MeSH term
Frequency | Condition_Probility | Humans | 178 | 0.0 |
Advisory Committees | 2 | 20.0 |
*Bioethics | 2 | 14.0 |
Embryo Research/*ethics | 2 | 22.0 |
*Ethical Theory | 2 | 25.0 |
Human Rights | 2 | 25.0 |
International Cooperation | 2 | 2.0 |
Military Medicine/*ethics | 2 | 22.0 |
Stem Cells | 2 | 1.0 |
War/ethics | 2 | 25.0 |
Aldosterone Synthase/genetics | 13 | 72.0 |
*Blood Pressure | 3 | 2.0 |
Calmodulin-Binding Proteins/*genetics | 2 | 8.0 |
Female | 82 | 0.0 |
Genotype | 42 | 0.0 |
Infant, Newborn | 11 | 0.0 |
Male | 94 | 0.0 |
*Polymorphism, Genetic/physiology | 2 | 100.0 |
Regression Analysis | 2 | 0.0 |
Adult | 50 | 0.0 |
Aldosterone/blood | 18 | 9.0 |
Blood Pressure | 7 | 1.0 |
Crossing Over, Genetic | 2 | 2.0 |
Glucocorticoids/*therapeutic use | 4 | 10.0 |
Middle Aged | 55 | 0.0 |
Pedigree | 17 | 0.0 |
Phenotype | 9 | 0.0 |
Pregnancy | 3 | 0.0 |
Steroid 11-beta-Hydroxylase/genetics | 11 | 64.0 |
Aldosterone Synthase/*genetics | 65 | 92.0 |
Angiotensinogen/genetics | 5 | 15.0 |
Case-Control Studies | 7 | 0.0 |
Echocardiography | 5 | 2.0 |
Heart Ventricles/pathology | 2 | 16.0 |
Peptidyl-Dipeptidase A/genetics | 5 | 6.0 |
*Polymorphism, Genetic | 30 | 0.0 |
Research Support, Non-U.S. Gov't | 119 | 0.0 |
Base Sequence/genetics | 4 | 1.0 |
Comparative Study | 12 | 0.0 |
Cytosine | 2 | 2.0 |
Double-Blind Method | 2 | 0.0 |
Receptor, Angiotensin, Type 1 | 7 | 5.0 |
Thymine | 2 | 3.0 |
Treatment Outcome | 3 | 0.0 |
Animals | 41 | 0.0 |
Cattle | 7 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Mice | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 39 | 0.0 |
Steroid 11-beta-Hydroxylase/*genetics | 24 | 70.0 |
Transfection | 18 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Aldosterone Synthase/metabolism | 2 | 66.0 |
Creatinine/blood | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Renin-Angiotensin System/*genetics | 7 | 14.0 |
Time Factors | 5 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
Aldosterone/metabolism | 2 | 10.0 |
Chromosome Mapping | 3 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Aldosterone Synthase/genetics/*metabolism | 3 | 100.0 |
Amino Acid Sequence | 15 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 3 | 2.0 |
Models, Molecular | 5 | 0.0 |
Molecular Sequence Data | 25 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Species Specificity | 3 | 0.0 |
Substrate Specificity | 3 | 0.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Aldosterone/*blood | 5 | 10.0 |
Alleles | 18 | 0.0 |
Cross-Sectional Studies | 5 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Gene Frequency | 21 | 0.0 |
Renin/*blood | 6 | 6.0 |
Binding Sites | 4 | 0.0 |
Mitochondria/enzymology | 3 | 2.0 |
Protein Structure, Secondary | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Steroid 11-beta-Hydroxylase/*chemistry | 2 | 100.0 |
Structure-Activity Relationship | 3 | 0.0 |
CHO Cells | 2 | 0.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Gene Conversion | 3 | 5.0 |
Haplotypes | 5 | 0.0 |
Introns | 5 | 0.0 |
Japan | 9 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Polymorphism, Genetic | 17 | 0.0 |
Aged | 30 | 0.0 |
Blood Pressure Monitoring, Ambulatory | 3 | 6.0 |
Exons/genetics | 4 | 0.0 |
Fludrocortisone/therapeutic use | 2 | 50.0 |
Heterozygote | 5 | 0.0 |
Introns/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Blotting, Southern | 9 | 0.0 |
In Vitro | 3 | 0.0 |
Kinetics | 4 | 0.0 |
Oligonucleotide Probes | 3 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Steroid 11-beta-Hydroxylase/biosynthesis | 2 | 100.0 |
Steroids/*biosynthesis | 4 | 7.0 |
Analysis of Variance | 5 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
Renin-Angiotensin System/genetics | 5 | 21.0 |
Renin-Angiotensin System/physiology | 2 | 4.0 |
Sodium/urine | 2 | 3.0 |
Hyperaldosteronism/*genetics | 5 | 100.0 |
Chimera | 2 | 1.0 |
Promoter Regions (Genetics) | 8 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Mutation | 19 | 0.0 |
Receptors, Angiotensin/genetics | 3 | 12.0 |
Renin/blood | 12 | 3.0 |
In Situ Hybridization | 3 | 0.0 |
Steroid 17-alpha-Hydroxylase/*genetics | 2 | 6.0 |
Aldosterone Synthase/deficiency/*genetics | 2 | 100.0 |
COS Cells | 6 | 0.0 |
Child, Preschool | 7 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Crossing Over, Genetic/*genetics | 2 | 22.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Aldosterone Synthase/*metabolism | 3 | 100.0 |
Steroid 11-beta-Hydroxylase/*metabolism | 4 | 100.0 |
Adrenal Hyperplasia, Congenital/*genetics | 2 | 8.0 |
Base Sequence | 28 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Steroid 11-beta-Hydroxylase/*genetics/metabolism | 2 | 40.0 |
*Crossing Over, Genetic | 2 | 6.0 |
Drug Resistance | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Exons | 12 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Polymerase Chain Reaction | 19 | 0.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
Reference Values | 8 | 0.0 |
Corticosterone/blood | 2 | 5.0 |
Steroid 11-beta-Hydroxylase/genetics/metabolism | 5 | 83.0 |
*Point Mutation | 6 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Gene Deletion | 3 | 0.0 |
Peptidyl-Dipeptidase A/*genetics | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Receptor, Angiotensin, Type 2 | 3 | 3.0 |
Adrenal Cortex Hormones/biosynthesis | 3 | 37.0 |
*Adrenal Hyperplasia, Congenital | 4 | 18.0 |
Prenatal Diagnosis | 2 | 1.0 |
Risk Factors | 7 | 0.0 |
Adolescent | 7 | 0.0 |
Age Factors | 3 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Receptors, Angiotensin/*genetics | 3 | 6.0 |
Aldosterone/*biosynthesis/blood | 4 | 80.0 |
Corticosterone/*biosynthesis/blood | 2 | 100.0 |
Hypertension/*blood/*genetics | 2 | 66.0 |
Immunohistochemistry | 3 | 0.0 |
Infant | 10 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Blood Pressure/genetics/physiology | 2 | 28.0 |
18-Hydroxycorticosterone/blood | 4 | 100.0 |
Aldosterone Synthase/*deficiency/*genetics | 2 | 100.0 |
Codon | 2 | 0.0 |
Angiotensin II/pharmacology | 3 | 4.0 |
Cell Line | 13 | 0.0 |
Mutation/physiology | 2 | 1.0 |
Potassium/pharmacology | 4 | 7.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
DNA/blood | 2 | 1.0 |
*Mutation | 9 | 0.0 |
Aldosterone/biosynthesis | 10 | 71.0 |
Hydrocortisone/metabolism | 2 | 6.0 |
Hypertension/*genetics | 9 | 8.0 |
Aldosterone Synthase/biosynthesis | 2 | 100.0 |
Hypertension/etiology | 2 | 4.0 |
Hypokalemia/etiology | 2 | 50.0 |
Corticotropin/metabolism | 2 | 5.0 |
Enzyme Activation | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Potassium/metabolism | 2 | 1.0 |
Steroids/metabolism | 3 | 9.0 |
Transcription, Genetic | 4 | 0.0 |
Aldosterone Synthase/biosynthesis/*genetics | 2 | 100.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
11-beta-Hydroxysteroid Dehydrogenases | 3 | 12.0 |
DNA Primers | 5 | 0.0 |
Hydrocortisone/biosynthesis | 6 | 37.0 |
Myocardium/*enzymology | 2 | 2.0 |
Rats | 12 | 0.0 |
Adrenalectomy | 2 | 4.0 |
Diagnosis, Differential | 2 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Steroid 17-alpha-Hydroxylase/genetics | 3 | 10.0 |
Molecular Biology | 2 | 0.0 |
Aldosterone/urine | 2 | 20.0 |
Europe | 2 | 0.0 |
Heart Rate/*genetics/physiology | 2 | 50.0 |
Potassium/urine | 2 | 5.0 |
Receptor, Angiotensin, Type 1/*genetics | 2 | 16.0 |
Sodium/*urine | 2 | 14.0 |
Hypertension/genetics | 2 | 8.0 |
Linear Models | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Genetic Markers | 3 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Finland | 2 | 0.0 |
Renin-Angiotensin System/*genetics/physiology | 3 | 33.0 |
Anthropometry | 2 | 0.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Baroreflex/genetics | 2 | 100.0 |
Cohort Studies | 4 | 0.0 |
Aldosterone Synthase/*deficiency/genetics | 3 | 100.0 |
Aldosterone/*biosynthesis | 11 | 68.0 |
Desoxycorticosterone/metabolism | 2 | 50.0 |
Hydroxylation | 4 | 1.0 |
Blood Pressure/*genetics | 6 | 10.0 |
*Cardiovascular Physiology | 2 | 7.0 |
Cercopithecus aethiops | 2 | 0.0 |
Adrenal Cortex/*physiology | 2 | 22.0 |
Steroid 11-beta-Hydroxylase/*physiology | 2 | 100.0 |
Adrenal Glands/metabolism | 2 | 4.0 |
Aldosterone/*metabolism | 3 | 30.0 |
Cells, Cultured | 7 | 0.0 |
Aldosterone Synthase/*genetics/metabolism | 3 | 100.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Amino Acid Substitution | 5 | 0.0 |
Hypertension/blood/enzymology/*genetics | 3 | 100.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Mixed Function Oxygenases/*deficiency | 10 | 62.0 |
Catalysis | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Hyperaldosteronism/enzymology/*genetics | 2 | 100.0 |
Potassium/blood | 4 | 4.0 |
Aldosterone/blood/urine | 2 | 50.0 |
Corticotropin/pharmacology | 2 | 3.0 |
Diastole | 2 | 2.0 |
Genetic Screening | 3 | 0.0 |
Metabolism, Inborn Errors/*genetics | 2 | 8.0 |
Aldosterone Synthase/*antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 2 | 6.0 |
Adrenal Glands/*enzymology | 2 | 15.0 |
Aldosterone Synthase/*biosynthesis | 2 | 100.0 |
Gene Expression Regulation, Enzymologic/physiology | 2 | 2.0 |
Sequence Deletion | 2 | 0.0 |
Sodium, Dietary/pharmacology | 2 | 50.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Adrenal Cortex/enzymology | 2 | 50.0 |
Angiotensin II/*pharmacology | 3 | 2.0 |
Potassium/*pharmacology | 2 | 20.0 |
*Alleles | 2 | 0.0 |
Arteriosclerosis/genetics | 2 | 6.0 |
Oligonucleotide Probes/genetics | 3 | 2.0 |
*Aldosterone Synthase | 4 | 100.0 |
Aldosterone Synthase | 16 | 80.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 3 | 2.0 |
Protein Conformation | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 8 | 1.0 |
Dexamethasone/*therapeutic use | 2 | 11.0 |
Adrenal Hyperplasia, Congenital | 2 | 40.0 |
Adrenal Cortex/*enzymology | 2 | 33.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
DNA | 2 | 0.0 |
Glucocorticoids/*biosynthesis | 2 | 66.0 |
Mineralocorticoids/*biosynthesis | 2 | 100.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Steroid Hydroxylases/*genetics/metabolism | 2 | 9.0 |
Steroid Hydroxylases/*genetics | 5 | 5.0 |
*Genes, Structural | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Codon/genetics | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Sulfonamides/pharmacology | 2 | 1.0 |
Cholesterol Side-Chain Cleavage Enzyme/genetics | 2 | 9.0 |
Angiotensinogen/*genetics | 2 | 2.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
